Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If this isnt validation that this thing is about to blow the fuck up.... I don't know what is. Had a 40% swing almost and is no climbing right back up like nothing.... Yall are some clowns lol.
Sure most of the Ihubbers held, but if anybody here didn't, ya'll are feeling super salt now that we are heading north again. Will close above .03 IMO.
LETS GOOOOOOOOOOOO
Anybody want to push this over .03 with me. I can take off 100k shares or so.
BOOOOOOMMMMM!!!! KEEP PUSHING PEOPLE. .03 and we out of here.
Dilution hasn't been bad the past week. S/O has remained stable at about 230mm. But I do agree, this went up hard a few weeks about and dilution was a huge problem. On any news and no dilution I expect .10s easily!
Still can't believe I got lucky enough to find this while it was still trading in the .003s.
Yes. Glad that somebody sees it the way I do. No PR's right now=massive uptick once the toxic debt is relieved and all the PR's that are in the pipeline now actually get released.
One of the reasons I love this company most is that once they get profitable, they will likely stay that way. PCTL's revenue is partly project dependent, but it is also largely based on monthly recurring service payments. As such, unlike many project based companies, their revenues should stay stable month to month which bodes well for price stability and sustainability.
Even if this company doesn't make a single sale in a month, they will still get paid on their other deals. As they continue to make sales (which they will), they will continue to grow this recurring base. If they go a month or two without a sale that doesn't automatically mean the company will have to dilute or take on debt as long as the recurring revenue can support the operations until they make additional sales.
The revenue streams that can be generated here are insane. SHMP should take a look at this model and run the business the same way. License the tech out. Retain ownership over the IP etc., and get those recurring payments.
It is this exact reason why I stopped trying to flip to accumulate. As greedy as I would love to be and get more shares, this thing takes off so fast and when news can drop any time, its just not worth it.
Glad to have more strong hands on board with us.
The CFO is not.
I saw the post that she was working on them. I didn't see that she said they would be on time. I personally hope they are delayed, unless the deal has closed already and they are waiting to announce it in the 10q rather than releasing an 8K. I want this deal to close before any news is released. Then let them open the floodgates with news.
Would not be surprised to see 10Q delayed. If so, that is a phenomenal sign in my mind as it means they are doing everything they can to get rid of notes before a massive spike in volume and price.
If this gets delayed, I will be adding another 300-500k depending on what the price settles at.
No no, I'm not too worried about it. It raises a question-mark in my mind for sure, but my day job is as a corporate/securities legal associate so I also know enough about registered agents to know that they have little to no effect on the management/operations/strategy of the company.
The fact that this is a pink sheet company that makes timely disclosures, files 8Ks, and is transparent about their dilutive activities is enough to generate credibility for me. I'll chalk the Roger Coleman thing up as an oversight and move on.
Not that it really matters, but I do hope that this Coleman situation gets clarified or addressed publicly by PCT. I will say this, when using a "commercial" registered agent, they often have no real connection or control over companies. This seems like one of those cases. I would like to see this clarified just to understand why they chose to use this guy and it would spur additional SH confidence.
Anyway, just my two cents. This in now way changes my outlook here. But I'm sure it may dissuade some from touching PCT, which is unfortunate.
Tried to flip 50K shares today... big mistake. Done trying that.... To those of you flipping trying to get more, I wish you luck. Luckily got back in without taking too much of a hit on those 50k shares.
Another way to look at it is based on potential. Sure the merger is great but IMO (I know many others disagree) it doesn't add a ton of value, from an operational perspective. Sure they get a new sales channel and reduce debt, but nothing about the merger changes the fundamental value of the product (which is huge).
PCTL currently has the manufacturing capacity to make and implement 40-50 systems a month (one of the articles talked about their capacity). While prices vary, my educated guess is that the company averages about $30k+ for each system (not sure the breakdown between the system and recurring leasing/license payments which has some effect on value).
$30k*45 systems*12= $16.2mm a year in revenue. Now since it is still a growing company, I would put a pretty high revenue multiple on it. With some OTCs you see ridiculous multiples (40x+). The norm for a blue-chip co is between 1-3x. Here, let's assume a conservative 5x.
5*16.2mm= 81mm. Then divide that by 230mm shares outstanding and you get a price of about $0.35. That does not include any sort of momentum or short squeezes if they occur, etc. Also, depending on your assumptions that may be slightly over valued or undervalued if you assume a more aggressive multiple/growth etc.
Man those of you getting shares down in the .011s right now, I'm jealous as hell. Those of you, if you're here, that are selling down there, are literal morons lol.
Everybody please go look at the chart for $CLSI. I'm sure some of you are in that play. It first took off about a month ago and then trended downward, much like $PCTL. If you cut off the recent spike, the chart would look near identical to PCTL...
$CLSI has approximately the same number of shares outstanding and has traded as high as .038ish. The kicker.... It is not a company that can revolutionize disease prevention. In fact, at this point it is not even a real operating company nor (to my knowledge) has a company been identified that is going to R/M into the shell.
This is not a bash on $CLSI, as R/M's are very lucrative plays. Had I been more liquid and been keeping up on research, I likely would have been in too. The real point of this post is to illustrate how ridiculous $PCTL's run is going to be. If a non-operating shell can hit .038 a company that has growing revenues in a revolutionary space can literally go 10x that I would hope. That would put us at about $.38....
I pray that we see another massive dip day... I will literally load every penny I can get my hands on into $PCTL on top of the position I am already holding.
Company is due to release 10Q next week. Unless they get the merger closed prior to releasing the 10Q, I wouldn't be surprised to see the 10Q delayed. If management stays in line with their current strategy, it would make no sense for them to drop a solid 10Q (which I believe will be the case) before the debt is settled since it will have the same affect on volume and the pps that a solid press release would. Plus, releasing a 10Q could risk spoiling any positive momentum associated with future releases since a lot of information will end up being disclosed there.
As much as the impatient hate it, I really think the company is being smart by not releasing anything. Generally in these types of situations, you see OTC mgmt release fluff news just to keep momentum going. While that is great and all short-term, I view that with great skepticism because it means they have no real positive items coming down the pipeline. PCT's lack of news leads me to believe they really do have something substantial coming and are waiting to release it at the perfect moment. Clearly they have things that they could talk about (i.e. innovation award, new deals, strategy, merger, etc.). So by not talking about some of the positive developments at a time when all eyes are on them, it tells me that they are working on shedding the toxic debt which will in turn give their upcoming releases much more effect on the pps.
If less debt and more sales doesn't get you excited, I don't know what does. Exciting things ahead in my opinion.
So many games being played here to get shares.... Gives me that much more confidence.
I just caught this..... quote taken from an article back in September 2018 (link below):
For a period of one year, beginning October 1, 2018, PCTL will deliver up to fifty (50) Hydrolyte®
generators to a central point of distribution in Florida, where the PCTL licensee and distributor will also
begin the launch of an extended trial through distribution of equipment and fluid solutions to a select
portion of the target market. The initial phase of the agreement calls for the delivery of ten (10)
Hydrolyte® generators to the central distribution center in Florida by October 1, 2018. The extended
trials will be aided by an agricultural specialist as further testing is performed and protocols are refined.
http://www.para-con.com/images/docs/PCTL-9-26-18.pdf
.... One agreement for one niche problem, 50 systems..... Literally, this system is helping eradicate some random crop disease, and that alone will potentially yield 50 systems worth of revenue. And this deal is done already. This isn't speculative, the agreement is set in stone. Whether 50 will actually be delivered, time will tell. But seeing as how companies have repeated orders and signed long-term contracts after trials, I would not be surprised to see 50 delivered + more.
This system can do a ton.... it has so many more applications than just healthcare. This is just my opinion naturally, but this company is one of the best speculative plays I've ever seen on the OTC. If they can walk away from toxic debt and keep their share structure close to AS-IS, I'm holding my position for a long time because it will literally retire me.
Interesting find on the OTC News page. Plans to start a fresh news feed with a bombshell release maybe? One can hope....
The more I research this company and industry the more excited I get. If any of you are looking for some bedtime reading to make you fall asleep, I would definitely advise reading the patent. Although it's boring, it also explains why their technology is so valuable. Per the patent, their antibiotic solution is able to kill HIV...
The only thing this company is missing is exposure to potential customers. If any of you know doctors/hospital admin/food processing cos/oil and gas mgmt/school boards etc., I would definitely pass along this information.
Schools especially interest me. You have the rapid spread of things like measles and other infections going on right now in schools. And schools also seem to be the most accessible customer when comparing They might not be the biggest market, but to generate some initial cash flow to grow the healthcare, food processing, and oil sales, I think its a no-brainer.
Also.... Just let this sink in for a second... $KBLB had a market cap of like $400mm at it's peak. it has 4x our shares outstanding. Sure maybe there is an argument that KBLB has a more revolutionary product (I don't believe that, but some might). KBLB now has a market cap of $192mm. And their revenue in all of 2018 was the same as our revenue in the last 6 months.... so let that sink in.... We are on track to do 2x KBLB's revenue this year but are valued at 2/192 the price.
If that seems off to you, its because it is. KBLB is seriously overvalued currently and PCTL is currently extremely undervalued. Even if PCTL had half the mkt cap that KBLB, the price would still be at .35+. The potential returns here are insane.
IMO.
I would not be surprised if we didn't see any news until after the conference is over. The 8K spells it out. The company is doing all it can to get rid of the toxic debt without screwing the share structure of the company up. Releasing news would likely result in note holders converting more shares to sell.
By not releasing news, which in turn keeps volume and price at average levels, it gives the company the ability to relieve themselves of the toxic debt properly, which then clears the runway. Once the deal is closed, I expect to see a massive 10Q right around the middle of the month as well as additional sales/pipeline news. It also creates a strong, patient shareholder base that is in this Co. for longer than 3 hours which takes away a significant amount of volatility.
By fixing the balance sheet first, the company clears major obstacles out of the way for sustainable upward movement.
PCTL's strategy is actually smart. They are building an established sales network in Europe, Canada, U.S., etc. Now that they have an established working product, all it takes now is some gas (capital) on the fire and its going to spread like no other. Their product is extremely scalable. They can manufacture themselves or license the design out for others to manufacture and literally rake in the money....
For those that want to see how this might look, go look at $KBLB. That Co. has no real revenues (based on my limited knowledge so please correct me if I'm wrong) and substantially more shares outstanding. Yet it was sustaining .40s-.50s no problem.
ANB Description taken from their website:
"Today, the Canadian OTC market is edging over $40 billion, and is a heavily regulated industry. ANB Canada has helped clients navigate the sector for two decades, assisting with manufacturers’ needs to move into the North American food/drug/mass landscape. ANB is the go-to for niche over-the-counter retail distribution, offering a turnkey sales and distribution service for manufacturers looking to enter the Canadian marketplace. ANB propels relationship management at the brand level, particularly when it comes to assisting a new brand—this is where ANB has established itself as a pillar in the industry.
The fundamental service offering from ANB prepares clients to operate in Canada, where consumers are progressively product-savvy. The company has seen its markets change as dictated by how consumer packaged goods in OTC has evolved—this evolution is driven primarily by consumer brand awareness, loyalty and aggressive retail promotion. Manufacturers must be able to generate brand awareness for knowledgeable consumers, and at the same time, navigate Canadian regulatory compliance guidelines. This is where ANB clients enjoy superior service: from bilingual packaging, stringent Health Canada compliance regulations, to becoming registered vendors with Canadian retailers; taking these steps in the OTC market can be a difficult process without a household name brand. ANB offers these services and more, including networking and securing meetings with retail buyers.
ANB has risen above the competition in leaps and bounds in the past twenty years, and much of this progression is a direct result of an excellent in-house team. Non-competitive retailers that previously only focused on other categories (i.e. grocery) are now attempting to enter the OTC market. This has made the Canadian market even more competitive. However, with its knowledgeable and personalized approach to client development, ANB has taken clients to the next levels of success—clients are in the expert care of ANB personnel. Every ANB client, regardless of size, is given the same dedication and ANB has earned a pristine reputation for representing clients with unwavering commitment."
If this doesn't scream synergies.... I don't know what does. Seeing as how PCTL's product is revolutionary, what better market to go to than a progressive one like Canada. And who better to partner with than a company that has had success with navigating the regulatory framework and selling into the Canadian Healthcare market.
I figured I would do some real DD here since most of the board is preoccupied with speculation about news and share structure. Jacqueline Boddaert signed the extension letter today (LinkedIn link below). She seems to be an associate of Ron with some equally impressive credentials. So now we know we are not only getting Ron, but also potentially getting Jacqueline as well.
Taken directly from her LinkedIn:
"Over 25 years of diversified business experience as a senior executive in the financial services, packaged goods and pharmaceutical industries. Ms. Boddaert previously served as Chief Executive Officer for Griffin Skye, CEO, President and Ultimate Designated Person for Monarch Wealth Corporation as well as President of Monarch Wealth Assurance Agencies Inc. and Monarch Wealth Deposit Group Inc. These businesses collectively managed over $700 million of client assets and focused on the sale of investment products and solutions to a mid-net worth client market."
Now I looked into Griffith Skye... They acquired ANB Canada (one of Ron's companies) back in 2016 I think. A description of ANB Canada is as follows (taken from marketinsider):
"The Corporation offers turnkey over-the-counter (“OTC”) sales and distribution services to manufacturers in the Canadian Food, Drug and Mass marketplace. The Corporation not only markets, sells, warehouses and distributes consumer OTC brands, but also helps manufacturers in a number of other areas including navigating Canadian regulatory guidelines."
So basically, it seems that ANB Canada is more than likely behind Ontario HoldCo. seeing as how both Ron and Jacqueline are tied to this transaction. Seeing as how ANB Canada is a well established sales and distribution network, I can only imagine they would take a chance on this if they saw real potential..... Regardless of if the deal closes, the fact that they are extended LOI's and even offering to take on PCTL should offer some validation to those that are skeptical.
Will work on additional information in subsequent posts. Don't want to create a novel here.
https://www.linkedin.com/in/jacqueline-boddaert-89569a3/
Hell yeah its exciting!!! I'm amped about this co. News or no news it doesn't change my opinion. Bring on the shorts please because when news does get released BOOOOOOMMMM.
I could see an 8k Thursday night again. Thinking about it, it makes the most sense. You would have a massive run on Friday and for those not paying attention to the market, word would spread as people see friends and family over the weekend which drives another big day the following Monday and then a full week to keep the momentum going.
I was scrolling back and most of the 8ks that the company has posted were posted on a Wednesday or beyond. More often than note they have come on a Thursday or Friday.
Honestly, I'm not even mad if they delay this either. The more shorts we have the bigger the move since most people are accumulating and shares will be sparse as this thing begins to make big moves. Wouldn't be mad if the postponed news for a week or more if it meant more shorts came on board.
I don't disagree with what you are saying. Like I said, I think there are many benefits to having Ron on board. All I am saying is that even without him, it's not as if we are dead in the water. Jody Read built a $40mm a year sales business in the medical space. The rest of management has a ton of relevant experience and connections. They have built the product, generated sales, and built this all without Ron. Sure Ron could add some value, but who is to say the current team can't generate similar value.
My point being that with or without this deal, I don't think there is reason to panic. Listing on the Canadian exchange is as simple as a R/M with a shell company on the exchange. Current management can accomplish that. Current management can also continue to grow sales, albeit it may or may not be at a slower pace (something well never be able to know for sure).
The major kicker is the debt. I would much prefer Ron's debt capital to Power Up Lending lmao. So unless the company can find traditional inventory lending, I agree that Ron offers something essential with retiring debt. I just don't want to see the share structure go to hell in the process. If I see the authorized shares get bumped to anything above 500mm without restrictions on management sales, I am out of here. Too hard to get the price to move more than a few cents here or there.
I honestly don't understand why everybody is so focused on this merger. Yeah, Ron is great and brings a lot to the table, but it doesn't change the fundamental reason I invested in this company. The technology with or without Ron is proven. Sales and growth have been realized without Ontario. As a shareholder, I would honestly rather take my chances without Ron if it meant we kept a super tight share structure.
The only reason the merger is being focused on is because it tipped people off to the company. I somehow got lucky and stumbled upon this beauty a few days before the 8k came out. and I pulled the trigger on a substantial position then because I knew the only reason that it was so cheap was that it had fallen through the cracks. The only thing the 8k did was generate some attention and allowed others to see what great potential this had, with or without Ontario.
Just my thoughts, but feel as if the big picture is being missed here slightly. With or without the merger, it doesn't change the value behind this company. It has the tech, it has revenues, and it solves a major problem.
There are really only two options at this point IMO, unless the company bumps the authorized shares up. 1) Ontario is buying the shares in the open market for the current price, in which case they are getting a hell of a deal seeing as how they were originally going to have to buy shares for .04 (thats on the market for not pushing the price up higher); or 2) the deal is restructured.
I really wouldn't be surprised to see Ontario taking less of a stake in the company.... At this point the toxic debt is converted and most of the other notes are with related parties so they are free to defer payback for as long as they please. The only need for Ontario from a financial perspective at that point is for the $750k working capital portion. Now with that being said, I would still like Ontario to have some sort of vested interest in PCT, as I think Ron brings additional experience that would be valuable. But with respect to the .04 convertible loan and option agreement, I would be ecstatic if those were restructured to be slightly less dilutive.
Time will tell.
Seems I was mistaken, that article seems to imply the cost of a large volume system is $60k. Again, this pushes revenue numbers up even further.
If I'm not mistaken, in one of the articles that talks about the option agreements they signed with one of their customers it lists the price of a unit at $20k-$30k. Now I don't know if these are the same units that go into hospitals but I would imagine a hospital project is $10k or more for the build out and this doesn't include any recurring licensing revenue, training, replacement products etc.
When I was doing the math, I figured that if you could get 10% of hospitals and doctors offices, that would be around 2000 offices or so. In each office I assumed that you would have two or more systems in place. If you assumed 2000 offices * 2 per office average * $20k for each system, that's $80mm in revenue alone. If you assume that hospitals will have more than 2 systems and that this company can capture more than 10% of the market (very feasible) then you are talking hundreds of millions of revenue.
This won't happen overnight. But if we are talking pure potential here.... $16mm is a drop in the hat compared to what the realistic accessible market potential is. Not to mention, this does not include any revenue generated from assisted living, schools, food processing, oil and gas, agriculture, etc.
Not ignorant at all, my friend. Very accurate statement.
What's the point of selling right now. Dilution almost done, if not done already. Sure people will liquidate if news of closing doesn't happen but that doesn't change the fact that this company could announce new deals any day which would push the price right back to these levels. The down side risk at these prices is minimal at best.
Ask Rory what happens if you are patient and hold PCTL. Sounds like doing so generates nice returns.....
Not sure if anybody here uses google trends or not. Typed in "PCTL" to the search to see what search traffic is looking like day to day.
When I started monitoring the search trends last week, the only state that registered any substantial search traffic was CA. As of today however, the projection for "PCTL" search popularity is forecasting a major uptick and the interest from TX, FL, and NY is rapidly rising. When I checked the trends earlier today NY's interest was in the 50's. As of this post, NY's interest had skyrocketed into the 80's. Could be generating some real attention from Wall St. institutional investors.
Wouldn't be surprised after the TIPS press release. Those are the types of things that the general public generally glosses over, but hedge funds who invest in the healthcare space follow religiously.
https://trends.google.com/trends/explore?geo=US&q=pctl
Even if this deal doesn't go through... since most of the toxic debt will be off the balance sheet anyway after the conversions that have taken place, the only thing we miss out on is $750k for working cap. This deal has some benefits, but it really isn't a make or break situation.
Just for the record for flippers and bid-wackers, here is how irrational selling is currently.
As of March 31, 2019 there were 45mmish shares outstanding. On April 1, 2019 the price of $PCTL ranged between .15-.18. For simplicity, at a price of .165*45mm, that gives a market cap of about $8mm.
Between March 1 and now, we know the following: (1) we know the company has shed toxic debt; (2) we know that they have partnered with a badass from Canada, among other notable sales reps; (3) they have made additional sales, with options and talks to expand even more; (4) revenue has increased, not decreased. More simply put, the company should be more valuable today based on these developments, not less.
$8mm/195mmish shares (most recent number I saw on the board) equates to a share price of about $.04 (what a coincidence). And even that is understated, as it assumes no growth in the value of the company, which we just established is a poor assumption. Even by slapping the ask currently, you're still getting shares that will appreciate by well over 200% when these notes are all converted and the shares are accumulated properly.
Even if you wanted to consider things on a revenue basis... The Co. is increasing sales exponentially. Assuming no growth on a TTM basis, revenue is 400k. Since they were only operating for two of those months, I am going to extrapolate and say that revenue should be twice that this year ($800k). Generally, for revolutionary tech plays that are just getting started a 10x revenue multiple is on the conservative side. Again, on that basis the Co. is worth about 8mm (again, no coincidence)... Valuation theory still applies to some extent when OTC Co's generate enough attention.
So, yes... please continue taking the price down. As soon as the dilution ends, you are going to see this thing shoot to .04 (likely more) and realize your impatience caused you to lose. Despite being the OTC, there are opportunities that can be priced properly and liquid. If you can't recognize that this is one of those opportunities, you really shouldn't be playing in the OTC at all.